×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
NASDAQ:IMUX

Immunic Stock Forecast, Price & News

$3.77
+0.30 (+8.65%)
(As of 07/5/2022 04:00 PM ET)
Add
Compare
Today's Range
$3.41
$3.79
50-Day Range
$3.13
$7.87
52-Week Range
$2.52
$14.50
Volume
178,629 shs
Average Volume
480,175 shs
Market Capitalization
$115.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.75

Immunic MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
476.9% Upside
$21.75 Price Target
Short Interest
Healthy
6.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$127,380 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.86) to ($3.03) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.78 out of 5 stars

Medical Sector

627th out of 1,428 stocks

Pharmaceutical Preparations Industry

306th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive IMUX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter.

Immunic logo

About Immunic (NASDAQ:IMUX) Stock

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

IMUX Stock News Headlines

Immunic, Inc. (NASDAQ:IMUX) Short Interest Update
Why is Immunic (IMUX) Stock Plunging 40% Today?
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMUX
Employees
55
Year Founded
N/A

Company Calendar

Last Earnings
11/04/2021
Today
7/05/2022
Next Earnings (Estimated)
8/05/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$21.75
High Stock Price Forecast
$39.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+476.9%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Net Income
$-92,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.84 per share

Miscellaneous

Free Float
29,013,000
Market Cap
$115.14 million
Optionable
Not Optionable
Beta
2.18














Immunic Frequently Asked Questions

Should I buy or sell Immunic stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Immunic stock.
View analyst ratings for Immunic
or view top-rated stocks.

What is Immunic's stock price forecast for 2022?

4 analysts have issued 12 month price objectives for Immunic's shares. Their IMUX stock forecasts range from $9.00 to $39.00. On average, they expect Immunic's share price to reach $21.75 in the next year. This suggests a possible upside of 476.9% from the stock's current price.
View analysts' price targets for Immunic
or view top-rated stocks among Wall Street analysts.

How has Immunic's stock performed in 2022?

Immunic's stock was trading at $9.57 on January 1st, 2022. Since then, IMUX shares have decreased by 60.6% and is now trading at $3.77.
View the best growth stocks for 2022 here
.

When is Immunic's next earnings date?

Immunic is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for Immunic
.

How were Immunic's earnings last quarter?

Immunic, Inc. (NASDAQ:IMUX) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.05. During the same quarter last year, the firm earned ($0.70) earnings per share.
View Immunic's earnings history
.

Who are Immunic's key executives?

Immunic's management team includes the following people:
  • Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A, Exec. Chairman (Age 51, Pay $426.62k)
  • Dr. Daniel Vitt, CEO, Pres & Director (Age 54, Pay $621.67k) (LinkedIn Profile)
  • Mr. Glenn Whaley CPA, Chief Financial Officer (Age 54, Pay $448.48k) (LinkedIn Profile)
  • Dr. Andreas Muehler M.D., Ph.D., Chief Medical Officer (Age 58, Pay $538.19k)
  • Dr. Hella Kohlhof, Chief Scientific Officer (Age 49)
  • Jessica Breu, Head of Investor Relations & Communications
  • Mr. Inderpal Singh, Gen. Counsel (Age 56)
  • Mr. Patrick Walsh, Chief Bus. Officer (Age 39)

What other stocks do shareholders of Immunic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunic investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV), Moderna (MRNA), CymaBay Therapeutics (CBAY), NIO (NIO), NVIDIA (NVDA), TG Therapeutics (TGTX) and Ampio Pharmaceuticals (AMPE).

What is Immunic's stock symbol?

Immunic trades on the NASDAQ under the ticker symbol "IMUX."

How do I buy shares of Immunic?

Shares of IMUX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunic's stock price today?

One share of IMUX stock can currently be purchased for approximately $3.77.

How much money does Immunic make?

Immunic (NASDAQ:IMUX) has a market capitalization of $115.14 million. The company earns $-92,940,000.00 in net income (profit) each year or ($3.13) on an earnings per share basis.

How many employees does Immunic have?

Immunic employs 55 workers across the globe.

How can I contact Immunic?

Immunic's mailing address is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. The official website for Immunic is www.immunic-therapeutics.com. The company can be reached via phone at (332) 255-9818, via email at jessica.breu@immunic.de, or via fax at 858-673-6843.

This page (NASDAQ:IMUX) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.